Clinical Trial Update: Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. [Phase 1]

View source ↗

Summary

A completed Phase 1 study of the AKT inhibitor AZD5363 (ipatasertib) in metastatic castration-resistant prostate cancer. The trial evaluated safety, tolerabilit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AZD5363 (ipatasertib) (ipatasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy, | Phase 1 | Status: COMPLETED